ClinicalTrials.gg
Not yet recruitingNCT07824986sTEADfastUpdated Sep 17, 2026

A Phase 3 Trial in Advanced Epithelioid Mesothelioma

A Phase 3 interventional study of VT3989 and gemcitabine in Pleural Mesothelioma and Mesothelioma, sponsored by Vivace Therapeutics, Inc. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Vivace Therapeutics, Inc · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.

Read the detailed description

Approximately 350 participants will be randomized 1:1 to VT3989 (Arm A) or Investigator's choice chemotherapy with gemcitabine or vinorelbine (Arm B).

VT3989 will be administered orally at 100 mg once daily for 2 weeks on treatment followed by 2 weeks off treatment in each 4-week cycle. Comparator treatment will be gemcitabine or vinorelbine using the protocol-specified regimen or local prescribing/institutional practice.

The trial includes screening, treatment, safety follow-up, and survival follow-up periods. A QTc Sub-Study will evaluate cardiac repolarization using time-matched pharmacokinetic samples and ECGs in approximately 25 Arm A participants. Overall survival is the primary endpoint; BICR-assessed progression-free survival is the key secondary endpoint.

02

Conditions studied

  • Pleural Mesothelioma
  • Mesothelioma

Keywords

  • Mesothelioma
03

In context

Mesothelioma, Malignant

339 studies on the registry are indexed under Mesothelioma, Malignant; 64 are open to participants now.

This study's planned enrollment of 350 is above the median of 39 across 271 interventional studies indexed under Mesothelioma, Malignant.

Browse Mesothelioma, Malignant studies →

Lead sponsor

Vivace Therapeutics, Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age 18 years or older at .
  • confirmed advanced epithelioid pleural mesothelioma previously treated with platinum-based systemic chemotherapy and immunotherapy, given sequentially or concurrently.
  • Radiologically by modified v1.1 or RECIST v1.1.
  • : 0-1.
  • Adequate organ functions, including the liver, kidneys, and hematopoietic system.

Exclusion criteria

Exclusion Criteria:

  • Active or primary CNS (central nervous system) tumors.
  • History of
  • Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Known positive or active or
  • cardiovascular disease and prior exposure to cardiotoxic agents
  • (QTcF) interval > 470 msec (using Fridericia's correction formula).
  • Women who are pregnant or breastfeeding
  • Non-pleural mesothelioma at initial diagnosis or an aggressive histologic type such as sarcomatoid or biphasic mesothelioma.
  • Prior treatment with a TEAD inhibitor, including VT3989 or another agent targeting the same molecular pathway.
  • Prior receipt of both comparator treatments, gemcitabine and vinorelbine, alone or in combination, or known to both. A participant who received only one comparator may enroll but must not be assigned to that same comparator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Arm A - VT3989

    VT3989 monotherapy in 28-day cycles until BICR-verified progression, unacceptable toxicity, withdrawal, or another protocol-specified reason.

    Drug: VT3989

  • Active comparator
    Arm B - Investigator's Choice Chemotherapy

    The Investigator selects 21-day cycle of gemcitabine or vinorelbine. Administration and dose modification may follow the protocol, local prescribing information, or institutional practice.

    Drug: gemcitabine · Drug: Vinorelbine

Interventions

  • DrugVT3989

    • 100 mg orally once daily for 2 weeks on treatment followed by 2 weeks off treatment (2W/2W) in each 4-week cycle

  • • 1,000 mg/m2 IV on Days 1 and 8 of each 3-week cycle, or per local prescribing information/institutional practice

  • • 25-30 mg/m2 IV on Days 1 and 8 of each 3-week cycle, or per local prescribing information/institutional practice

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time from randomization to death from any cause. Participants without an observed death will be censored at the last date known alive or the analysis cut-off date, whichever is earlier.

    Time frame: Approximately 32-35 months after first randomization

Secondary outcomes

  1. Progression-Free Survival by BICR

    Time from randomization to the first BICR-assessed radiologic progressive disease or death, using protocol-defined censoring rules.

    Time frame: From randomization through radiologic progression, death, up to approximately 3 years or more

  2. Treatment-Emergent Adverse Events and Serious Adverse Events

    Incidence and severity of Treatment-Emergent Adverse Events and Serious Adverse Events

    Time frame: From first dose through the safety follow-up visit, (28 days after the last dose), up to approximately 3 years or more.

  3. Disease-related symptoms and health-related quality of life outcomes

    Disease-related symptoms, treatment side effects, functioning, and health-related quality of life outcomes and time to deterioration.

    Time frame: Baseline through treatment and protocol-specified follow-up; up to approximately 3 years or more

  4. Overall Response Rate by BICR

    Overall Response Rate by BICR Proportion with best overall response of complete response or partial response by RECIST v1.1 and/or modified RECIST v1.1, assessed by BICR.

    Time frame: Tumor assessments during treatment and applicable follow-up; up to approximately 3 years or more

  5. Duration of Response

    Among participants with a complete or partial response, time from first documented response to progressive disease or death, with protocol-defined censoring.

    Time frame: From first documented response through progression, death, or analysis cut-off; up to approximately 3 years or more

  6. Disease Control Rate by BICR

    Proportion with best overall response of complete response, partial response, or stable disease by RECIST v1.1 and/or modified RECIST v1.1, assessed by BICR.

    Time frame: Tumor assessments during treatment and applicable follow-up; up to approximately 3 years or more

  7. Time to Response

    Time from randomization to the first documented complete or partial response by RECIST v1.1 and/or modified RECIST v1.1.

    Time frame: From randomization to first documented response; up to approximately 3 years or more

  8. EORTC QLQ-LC13

    Lung cancer- and treatment-related symptoms using the EORTC Quality of Life Questionnaire Lung Cancer Module 13.

    Time frame: Baseline through treatment and protocol-specified follow-up; up to approximately 3 years or more

  9. EQ-5D-5L

    Health status and health-related quality of life using the EuroQol 5 Dimension-5 Levels instrument.

    Time frame: Baseline through treatment and protocol-specified follow-up; up to approximately 3 years or more

  10. Time to Deterioration

    Time to protocol-defined deterioration in disease-related symptoms and health-related quality of life; detailed definition will be specified in the Statistical Analysis Plan.

    Time frame: From baseline/randomization through protocol-defined deterioration; up to approximately 3 years or more

Other outcomes

  1. Pharmacokinetic Evaluation - Cmax

    Peak plasma concentration of VT3989

    Time frame: Up to Cycle 9 (each cycle is 28 days)

  2. Pharmacokinetic Evaluation - AUC

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to Cycle 9 (each cycle is 28 days)

  3. Correlation between VT3989 exposure

    Correlation between VT3989 exposure

    Time frame: Up to Cycle 9 (each cycle is 28 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
Jan 1, 2031
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07824986
Lead sponsor
Vivace Therapeutics, Inc
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Sep 17, 2026

Study contacts

Arick Wong
Contact
vt3989-003@vivacetherapeutics.com
650-666-2753
Dereck Amakye
Contact
info@vivacetherapeutics.com
650-666-2753

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion